24698-57-5

Basic information

• Product Name: 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride
• Synonyms: 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride;3',4'-Methylenedioxy-α-pyrrolidinopropiophenone;MDPPP;1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone Hydrochloride;1-(3',4'-Methylenedioxyphenyl)-2-pyrrolidino-1-propanone Hydrochloride;MDPPP Hydrochloride;1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one hydrochloride;MDPPP(3',4'-Methylenedioxy-α-pyrrolidinopropiophenone)
• CAS NO: 24698-57-5
• Molecular Formula: C14H18ClNO3
• Molecular Weight: 283.75062
• Product Categories: Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;thpvp
• Mol File: 24698-57-5.mol
• Article Data: 1

Chemical Properties

• Flash Point: 9℃
• Appearance: white to beige/
• Storage Temp.: 2-8°C
• Solubility: H2O: soluble10mg/mL, clear
• CAS DataBase Reference: 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride(24698-57-5)
• EPA Substance Registry System: 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride(24698-57-5)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-37/38-41-50
• Safety Statements: 26-39-61
• RIDADR: UN1230 - class 3 - PG 2 - Methanol
• WGK Germany: 3
• Hazardous Substances Data: 24698-57-5(Hazardous Substances Data)

Usage

Description

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride, also known as a stimulant designer drug, is a synthetic compound that shares a similar chemical structure with α-PPP and MDPV. It has been used as an ingredient in imitation ecstasy (MDMA) pills and is classified as a controlled substance due to its psychoactive effects.

Uses

Used in Pharmaceutical Industry:
3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride is used as an active ingredient in the production of stimulant designer drugs, particularly for the creation of imitation ecstasy (MDMA) pills. Its chemical structure and psychoactive properties make it a sought-after compound in the illicit drug market.
Used in Research and Development:
In the field of pharmaceutical research and development, 3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride serves as a valuable compound for studying the effects of stimulant designer drugs on the human body. This research can contribute to the development of new medications and a better understanding of the mechanisms behind their psychoactive effects.
Used in Drug Control and Regulation:
3',4'-Methylenedioxy-α-pyrrolidinopropiophenone Hydrochloride is used as a reference substance in the enforcement of drug control and regulation policies. Its identification and analysis play a crucial role in the detection and prevention of the distribution of controlled substances, as well as in the prosecution of individuals involved in the illegal drug trade.

Upstream product

• 28281-49-4 3,4-methylenedioxypropiophenone 

Relevant articles and documents

α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and uptake1 and uptake2 monoamine transporters

While classical cathinones, such as methcathinone, have been shown to be monoamine releasing agents at human monoamine transporters, the subgroup of α-pyrrolidinophenones has thus far solely been characterized as monoamine transporter reuptake inhibitors. Herein, we report data from previously undescribed α-pyrrolidinopropiophenone (α-PPP) derivatives and compare them with the pharmacologically well-researched α-PVP (α-pyrrolidinovalerophenone). Radiotracer-based in vitro uptake inhibition assays in HEK293 cells show that the investigated α-PPP derivatives inhibit the human high-affinity transporters of dopamine (hDAT) and norepinephrine (hNET) in the low micromolar range, with α-PVP being ten times more potent. Similar to α-PVP, no relevant pharmacological activity was found at the human serotonin transporter (hSERT). Unexpectedly, radiotracer-based in vitro release assays reveal α-PPP, MDPPP and 3Br-PPP, but not α-PVP, to be partial releasing agents at hNET (EC50 values in the low micromolar range). Furthermore, uptake inhibition assays at low-affinity monoamine transporters, i.e., the human organic cation transporters (hOCT) 1–3 and human plasma membrane monoamine transporter (hPMAT), bring to light that all compounds inhibit hOCT1 and 2 (IC50 values in the low micromolar range) while less potently interacting with hPMAT and hOCT3. In conclusion, this study describes (i) three new hybrid compounds that efficaciously block hDAT while being partial releasers at hNET, and (ii) highlights the interactions of α-PPP-derivatives with low-affinity monoamine transporters, giving impetus to further studies investigating the interaction of drugs of abuse with OCT1-3 and PMAT.